Tech Company Financing Transactions
Resolution Therapeutics Funding Round
On 10/3/2024, Resolution Therapeutics landed $83.4 million in Series B funding from Syncona and private investors.
Transaction Overview
Company Name
Announced On
10/3/2024
Transaction Type
Venture Equity
Amount
$83,400,000
Round
Series B
Investors
Syncona (Lead Investor)
Proceeds Purpose
The company intends to use the funds to advance its lead candidate, RTX001, an autologous, engineered, pro-regenerative macrophage cell therapy specifically designed to deliver transformative outcomes in patients with end-stage liver disease.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
Centre for Regenerative Medicine, University of Edinburgh, 5
Edinburgh, EH16 4UU
UK
Edinburgh, EH16 4UU
UK
Phone
Undisclosed
Website
Email Address
Overview
Our Vision: Unlocking the regenerative potential of macrophage therapy for the treatment of inflammatory and fibrotic diseases. Our initial focus is in end-stage liver disease. It is the only chronic disease still on the rise in western countries, and affects millions of people worldwide. Unfortunately, only supportive therapies are currently available.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Amir Hefni
Chief Financial Officer
Simon Ramsden
Chief Medical Officer
Cliff Brass
Chief Technical Officer
Amol Ketkar
Vice President
Eli Gilsohn
VP - Human Resources
Shazia Rahman
VP - Operations
Victor Dillard
VP - R & D
Lara Campana
Browse more venture capital transactions:
Prev: 10/3/2024: Truely venture capital transaction
Next: 10/3/2024: Kubus venture capital transaction
Share this article
Where The Data Comes From
We do our best to document tech company VC transactions. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs